Mylan's (MYL) Steps on EpiPen Do Not Go Far Enough - Wells Fargo's Maris
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Mylan's (MYL) EpiPen Saga Could Add More Supply Chain Volatility Moving Forward - Evercore
August 25, 2016 11:46 AM EDTEvercore ISI affirms Mylan (Nasdaq: MYL) with a Hold rating and $49 price target amid today's EpiPen cost-adjustment news.
The firm commented, Thanks to our top rated Specialty Pharma guru Umer Raffat (and CNBC) we are highlighting a slide Mylan is featuring (see below) in its... More
Mylan (MYL) calls active after cutting patient cost of EpiPen Auto-Injectors
August 25, 2016 10:03 AM EDTMylan (NASDAQ: MYL) September 46 and 49 calls are active on total call volume of 6K contracts (4K puts) after cutting the patient cost of EpiPen Auto-Injectors. August weekly call option implied volatility is at 68, September is at 36, October is at 34; compared to its 52-week range of 27 to 59.
... MoreMylan (MYL) CEO says healthcare bubble 'going to burst'
August 25, 2016 8:37 AM EDTMylan (NASDAQ: MYL) CEO says healthcare bubble 'going to burst'.
... MoreMylan (MYL) volatile amid CEO interview on CNBC
August 25, 2016 8:34 AM EDTMylan (NASDAQ: MYL) volatile amid CEO interview on CNBC. Last up 3.5%.
... MoreMylan (MYL) Announces Actions to Expand EpiPen Access; Includes Plans to Reduce Patient Cost
August 25, 2016 7:01 AM EDTMylan N.V. (Nasdaq: MYL) announced it is taking immediate action to further enhance access to EpiPen® (epinephrine injection, USP) Auto-Injector by expanding already existing programs in recognition of those patients who are facing the burden of higher out-of-pocket costs. The company is reducing the patient cost of EpiPen® Auto-Injector through the use of a savings card which will cover up to $300 for their EpiPen 2-Pak®. For patients who were previously paying the full amount of the company's list price for EpiPen®, this effectively reduces their out-of-pocket cost exposure by 50%. Mylan also is doubling... More
